tiprankstipranks
Trending News
More News >
Brainsway Ltd (BWAY)
NASDAQ:BWAY
US Market

Brainsway (BWAY) AI Stock Analysis

Compare
289 Followers

Top Page

BW

Brainsway

(NASDAQ:BWAY)

Rating:75Outperform
Price Target:
$14.50
▲(11.71%Upside)
Brainsway's strong financial performance, driven by revenue growth and balance sheet strength, is the primary driver of its stock score. Technical indicators signal bullish momentum but are tempered by overbought conditions. Valuation concerns arise from a high P/E ratio. Positive earnings call guidance supports future growth, though increased expenses and geopolitical risks need monitoring.
Positive Factors
Clinical Trial Results
The accelerated Deep TMS protocol resulted in outcomes comparable to the standard once-daily TMS protocol while requiring considerably fewer visits to the clinic.
Financial Performance
The company recorded $11.4M in top-line revenue, beating our forecast of $10.7M.
Regulatory Approval
BrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, increasing the upper age limit from 68 to 86 years, thus broadening the availability of Deep TMS therapy.
Negative Factors
Market Expansion Challenges
Risks include the inability to advance in other indications.
Market Risks
Risks include slower-than-projected market uptake of Deep TMS systems and failure to expand reimbursement and market access.

Brainsway (BWAY) vs. SPDR S&P 500 ETF (SPY)

Brainsway Business Overview & Revenue Model

Company DescriptionBrainsway (BWAY) is a medical technology company specializing in the development and commercialization of advanced non-invasive neurostimulation treatments for mental health disorders. The company is primarily focused on its flagship Deep Transcranial Magnetic Stimulation (Deep TMS) system, which is used for treating major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and other neuropsychiatric conditions. Operating in the healthcare sector, Brainsway's innovative solutions aim to improve the quality of life for patients by offering alternative treatment options that are effective and have minimal side effects.
How the Company Makes MoneyBrainsway generates revenue through the sale and leasing of its Deep TMS systems to healthcare providers, clinics, and hospitals worldwide. The company also earns income from recurring service and maintenance contracts associated with these systems. Additionally, Brainsway benefits from partnerships and collaborations with research institutions and healthcare organizations that further expand the use and development of its technology. Key revenue streams include direct sales, leasing agreements, and ongoing support services, which collectively contribute to the company's financial stability and growth.

Brainsway Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: 47.00%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflected strong growth in both revenue and system shipments, indicating robust demand for BrainsWay's Deep TMS systems. The company is making significant strides in clinical advancements and maintains a strong financial position with positive guidance for the year. However, increased operating expenses and potential geopolitical risks are concerns that need monitoring.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
BrainsWay reported $11.5 million in revenue for Q1 2025, marking a 27% increase year-over-year.
Increased System Shipments
The company shipped 81 Deep TMS systems, a 42% increase compared to the first quarter of 2024.
Strong Backlog and Future Visibility
BrainsWay has a backlog and remaining performance obligation totaling nearly $60 million, indicating clear visibility into future growth.
Clinical Advancements
The first TMS therapy approved for OCD and the first TMS device cleared by the FDA for anxious depression. Over 60% positive response rate for OCD patients.
Solid Financial Performance
Reported gross margin of 75%, increased operating income, and adjusted EBITDA margin, with positive cash flow from operations.
Positive Financial Guidance
Reiterating full-year 2025 financial guidance of $49 million to $51 million in revenue, representing 20% to 24% growth over 2024.
Negative Updates
Increased Operating Expenses
Sales and marketing expenses increased to $4.2 million from $3.8 million in Q1 2024, and research and development expenses rose to $2.3 million from $1.6 million.
Geopolitical and Tariff Uncertainties
Monitoring potential exposure to changes in international trade and tariff policies, though no material impact is expected currently.
Company Guidance
During the BrainsWay First Quarter 2025 earnings call, the company reported a revenue of $11.5 million, marking a 27% increase year-over-year. They shipped 81 Deep TMS systems, a 42% increase from Q1 2024, and maintained a gross margin of 75%. The company has a backlog and remaining performance obligations totaling nearly $60 million, reflecting strong demand and future growth visibility. BrainsWay's full-year 2025 revenue guidance is between $49 million and $51 million, representing a 20% to 24% growth over 2024, with anticipated operating income of 3% to 4% and adjusted EBITDA of 11% to 12%. The company is also focusing on expanding its market presence, enhancing customer engagement through multi-year agreements, and advancing its R&D roadmap to unlock new treatment indications.

Brainsway Financial Statement Overview

Summary
Brainsway has demonstrated strong financial performance with significant revenue growth, robust balance sheet with zero debt, and improved cash flow generation. The transition to positive net income and operational improvements are notable. However, historical volatility in earnings and cash flows remains a concern.
Income Statement
80
Positive
Brainsway has demonstrated strong revenue growth with a notable increase from $31.785 million in 2023 to $41.016 million in 2024, representing a growth rate of approximately 29%. The company has successfully transitioned from a negative net income in previous years to a positive $2.921 million in 2024. Gross profit margin improved to 74.54% in 2024, indicating efficient cost management. EBIT and EBITDA margins have also turned positive, signaling operational improvements. However, the historical volatility in earnings remains a concern.
Balance Sheet
85
Very Positive
Brainsway's balance sheet is robust, highlighted by zero total debt in 2024 and a substantial increase in stockholders' equity to $62.313 million. The equity ratio stands at a healthy 66.32%, reflecting strong financial stability and low leverage. The company's ample cash reserves of $69.345 million further enhance its financial flexibility. The absence of debt significantly reduces financial risk, but the company should continue to focus on sustainable equity growth.
Cash Flow
78
Positive
The company's cash flow performance has strengthened, with operating cash flow increasing significantly to $10.23 million in 2024, enabling positive free cash flow of $6.508 million. The operating cash flow to net income ratio is healthy, reflecting efficient cash generation. However, the historical volatility in free cash flow highlights the need for consistent cash flow generation. The improvement in free cash flow from negative figures in prior years is a positive trend.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue41.02M31.79M27.18M29.66M22.06M
Gross Profit30.58M23.48M20.05M23.06M17.00M
EBITDA5.47M-2.31M-11.45M-4.67M-3.46M
Net Income2.92M-4.20M-13.35M-6.46M-5.38M
Balance Sheet
Total Assets94.32M62.97M64.48M75.73M34.01M
Cash, Cash Equivalents and Short-Term Investments69.34M45.98M47.85M57.35M17.18M
Total Debt5.62M471.00K488.00K754.00K429.00K
Total Liabilities31.67M21.39M19.08M18.41M14.38M
Stockholders Equity62.31M41.58M45.40M57.32M19.63M
Cash Flow
Free Cash Flow6.50M-1.10M-7.82M-1.35M-3.91M
Operating Cash Flow10.30M1.28M-9.76M884.00K-1.44M
Investing Cash Flow30.31M-37.41M42.17M-42.22M-2.46M
Financing Cash Flow18.26M-1.03M-1.55M41.52M-1.03M

Brainsway Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.98
Price Trends
50DMA
10.41
Positive
100DMA
10.04
Positive
200DMA
9.86
Positive
Market Momentum
MACD
0.74
Negative
RSI
68.65
Neutral
STOCH
85.16
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BWAY, the sentiment is Positive. The current price of 12.98 is above the 20-day moving average (MA) of 11.65, above the 50-day MA of 10.41, and above the 200-day MA of 9.86, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 68.65 is Neutral, neither overbought nor oversold. The STOCH value of 85.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BWAY.

Brainsway Risk Analysis

Brainsway disclosed 67 risk factors in its most recent earnings report. Brainsway reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Brainsway Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$244.51M59.907.41%26.86%
57
Neutral
$210.43M-52.87%-4.16%12.79%
MYMYO
53
Neutral
$77.71M-35.68%69.17%39.01%
53
Neutral
$157.48M-76.01%25.62%11.86%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
50
Neutral
$195.58M271.41%85.03%53.73%
46
Neutral
$80.77M-94.65%-5.86%50.76%
46
Neutral
$80.77M-94.65%-5.86%50.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BWAY
Brainsway
12.80
7.00
120.69%
CTSO
Cytosorbents
1.00
0.09
9.89%
CTSO
Cytosorbents
1.00
0.09
9.89%
MYO
Myomo
2.08
-0.79
-27.53%
TLSI
TriSalus Life Sciences
4.90
-0.91
-15.66%
CVRX
CVRx
6.46
-5.91
-47.78%
SGHT
Sight Sciences
4.16
-2.04
-32.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025